About Theravance Biopharma (NASDAQ:TBPH)
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TBPH
CUSIPN/A
Phone650-808-6000
Debt
Debt-to-Equity Ratio1.94%
Current Ratio6.05%
Quick Ratio5.79%
Price-To-Earnings
Trailing P/E Ratio-4.19
Forward P/E Ratio-4.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.39 million
Price / Sales81.54
Cash FlowN/A
Price / CashN/A
Book Value$2.13 per share
Price / Book10.75
Profitability
EPS (Most Recent Fiscal Year)($5.45)
Net Income$-285,400,000.00
Net Margins-1,855.42%
Return on Equity-136.86%
Return on Assets-55.45%
Miscellaneous
Employees340
Outstanding Shares54,800,000
Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions
What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How were Theravance Biopharma's earnings last quarter?
Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing analysts' consensus estimates of ($1.15) by $0.49. The biopharmaceutical company had revenue of $4.52 million for the quarter, compared to the consensus estimate of $3.71 million. Theravance Biopharma had a negative return on equity of 136.86% and a negative net margin of 1,855.42%. View Theravance Biopharma's Earnings History.
What price target have analysts set for TBPH?
6 analysts have issued 12-month price objectives for Theravance Biopharma's stock. Their predictions range from $22.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $43.3333 in the next year. View Analyst Ratings for Theravance Biopharma.
What are Wall Street analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
- 1. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) An sNDA was filed for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. TBPH is entitled to receive an 85% economic interest in the royalties paid by GSK (Not Covered) on worldwide net sales; 2) Trelegy Ellipta was granted marketing authorization in Europe for the treatment of COPD; 3) in November, TBPH and MYL (Neutral) announced the submission of an NDA for revefenacin (TD-4208) in adults with COPD; 4) at the 2017 Annual CHEST Meeting, TBPH and MYL announced the presentation of additional positive efficacy data from the three- month, pivotal Phase 3 studies of revefenacin (TD-4208); 5) progression of inhaled JAK inhibitor into first-in-human studies in late-2018/early-2019; 6) TBPH expects to provide an update in 1H18 regarding its dialogue with U.S. and EU regulators on Phase 3 requirements for the velusetrag/TD-5108 program in gastroparesis; 7) cash and equivalents totaled ~$390MM at 12/31/17. This excludes the $100MM upfront payment received in February 2018, from the announced collaboration with Janssen (Not Covered)." (2/27/2018)
- 2. Needham & Company LLC analysts commented, "We recently hosted a series of mtgs w/ investors and Theravance mgmt. TD-1473 JAK inhibitor and GSK respiratory programs were typical starting points for discussion. Mgmt plans to initiate TD-1473 Phase 2b induction/ maintenance trial in Ulcerative Colitis in mid-2018. Initial data from TD-1473 Phase 1b trial in this indication are consistent w/activity in our opinion. Number of doses and patients in Phase 2b trial will depend on data from additional Phase 1b cohorts, which mgmt has not yet seen. GSK launched Trelegy for COPD last month (5.5-8.5% royalty to Theravance). Significant time also spent on TD-9855 and velusetrag, both of which appear on path for Phase 3 initiation in 2018. Reiterate BUY. We believe stock is undervalued ($1.3B EV), given continued maturation of diversified pipeline." (12/5/2017)
- 3. According to Zacks Investment Research, "Theravance has only one marketed product in its portfolio, Vibativ. Though Vibativ continues to perform well, the company’s sole dependence on the drug for growth is concerning. Moreover, its pipeline programs targeting the therapeutic areas are highly competitive which could affect the company’s operating results. Also, any agreement termination might be a huge setback for the company, as had been the case in the past. However, we are positive on Theravance’s efforts to expand the Vibativ’s label, which, if approved for additional indications, would be commercially significant. Further, Theravance’s collaboration agreement with Mylan for revefenacin, is a big positive. Its shares have outperformed the industry so far this year." (10/10/2017)
Who are some of Theravance Biopharma's key competitors?
Some companies that are related to Theravance Biopharma include Evotec A.G. (EVTCY), Puma Biotechnology (PBYI), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), AnaptysBio (ANAB), Intercept Pharmaceuticals (ICPT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Corcept Therapeutics (CORT), Motif (MTFB), Aimmune Therapeutics (AIMT) and Insmed (INSM).
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the folowing people:
- Mr. Rick E. Winningham, Chairman & CEO (Age 58)
- Ms. Renée D. Galá, CFO, Sr. VP & Treasurer (Age 46)
- Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 58)
- Dr. Sharathchandra S. Hegde Ph.D., Sr. VP of Research (Age 54)
- Dr. Phillip D. Worboys Ph.D., Sr. VP of Translational Science (Age 48)
Has Theravance Biopharma been receiving favorable news coverage?
News stories about TBPH stock have been trending somewhat positive on Thursday, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Theravance Biopharma earned a daily sentiment score of 0.22 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Theravance Biopharma?
Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Theravance Biopharma's stock price today?
One share of TBPH stock can currently be purchased for approximately $22.72.
How big of a company is Theravance Biopharma?
Theravance Biopharma has a market capitalization of $1.33 billion and generates $15.39 million in revenue each year. The biopharmaceutical company earns $-285,400,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Theravance Biopharma employs 340 workers across the globe.
How can I contact Theravance Biopharma?
Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]
MarketBeat Community Rating for Theravance Biopharma (TBPH)
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Theravance Biopharma (NASDAQ:TBPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Theravance Biopharma in the last 12 months. Their average twelve-month price target is $43.3333, suggesting that the stock has a possible upside of 89.23%. The high price target for TBPH is $55.00 and the low price target for TBPH is $22.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 3.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $43.3333 | $42.8333 | $42.6667 | $46.80 |
| Price Target Upside: | 89.23% upside | 52.70% upside | 59.20% upside | 38.42% upside |
Theravance Biopharma (NASDAQ:TBPH) Consensus Price Target History
Theravance Biopharma (NASDAQ:TBPH) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Theravance Biopharma (NASDAQ:TBPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Theravance Biopharma (NASDAQ TBPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 85.97%
Theravance Biopharma (NASDAQ TBPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/6/2017 | Bradford J Shafer | EVP | Sell | 14,670 | $30.77 | $451,395.90 | 134,327 |  |
| 8/21/2017 | Frank Pasqualone | SVP | Buy | 4,000 | $26.34 | $105,360.00 | 213,180 | |
| 8/11/2017 | Henrietta Fore | Director | Buy | 6,000 | $23.99 | $143,940.00 | 24,000 | |
| 8/11/2017 | Rick E Winningham | CEO | Buy | 10,000 | $24.50 | $245,000.00 | 866,377 | |
| 3/7/2017 | Brett K Haumann | SVP | Sell | 424 | $30.80 | $13,059.20 | 163,895 | |
| 3/6/2017 | Brett K Haumann | SVP | Sell | 13,576 | $31.52 | $427,915.52 | 163,895 | |
| 8/25/2016 | Brett K Haumann | SVP | Sell | 4,491 | $27.99 | $125,703.09 | 188,293 | |
| 8/22/2016 | Bradford J Shafer | EVP | Sell | 49,122 | $27.46 | $1,348,890.12 | 241,686 | |
| 8/19/2016 | Brett K Haumann | SVP | Sell | 9,509 | $27.97 | $265,966.73 | 197,391 | |
| 3/14/2016 | Plc Glaxosmithkline | Major Shareholder | Buy | 1,301,015 | $23,028,000.00 | $29,959,773,420,000.00 | | |
| 10/7/2015 | Plc Glaxosmithkline | Major Shareholder | Buy | 44,574 | $607,544.00 | $27,080,666,256.00 | | |
| 8/18/2015 | Burton G Malkiel | Director | Buy | 10,000 | $12.92 | $129,200.00 | | |
| 8/18/2015 | Junning Lee | VP | Buy | 9,000 | $12.90 | $116,100.00 | | |
| 8/17/2015 | Renee D Gala | CFO | Buy | 10,000 | $12.18 | $121,800.00 | | |
| 8/17/2015 | Rick E Winningham | CEO | Buy | 80,000 | $11.86 | $948,800.00 | | |
(Data available from 1/1/2013 forward)
Theravance Biopharma (NASDAQ TBPH) News Headlines
| Source: |
|
Theravance Biopharma (NASDAQ:TBPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Theravance Biopharma (NASDAQ:TBPH) Income Statement, Balance Sheet and Cash Flow Statement
Theravance Biopharma (NASDAQ TBPH) Stock Chart for Thursday, April, 19, 2018
Loading chart…
